Company: TELO
Filing Date: 2025-08-27
Form Type: 8-K
Source: 0001641172-25-025688
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-27
Form: 8-K
Item: Item 8.01
Chunk 1
---
 master growth-control circuits that cancers frequently hijack as a “fuel
line” for unchecked proliferation and treatment resistance. Unlike potent Tankyrase inhibitors, which can shorten telomeres and
pose systemic safety risks, Telomir-1’s modest activity may allow disruption of cancer’s fuel line without compromising telomere
biology. Supporting this distinction, previously reported data from a validated Werner Syndrome accelerated-aging in vivo model showed
that Telomir-1 significantly elongated telomeres beyond healthy levels while also reversing abnormal DNA methylation, restoring youthful
gene regulation, and resetting the epigenetic clock.

Taken
together, the results support Telomir-1’s emerging profile as a potential first-in-class epigenetic therapy with a dual mechanism
of action

  Resetting                                                                               
  Modestly                                                                                

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                       TELOMIR                                       
  Dated:               By:                        /s/                
                       Name:                      Erez               
                       Title:                     Chief